DUSP1 promotes pancreatic cancer cell proliferation and invasion by upregulating nephronectin expression-Reference-Cited by-同舟云学术

DUSP1 promotes pancreatic cancer cell proliferation and invasion by upregulating nephronectin expression

Published:2023-08-23 Issue:6 Volume:25 Page:681-690
ISSN:1765-2839
Container-title:Oncologie
language:en
Short-container-title:

Author:

Chen Yanlin¹,Ma Yunfei¹,Tang Yuting¹,Jin Yucui¹,Zhu Yi²,Ma Changyan¹

Affiliation:

1. Department of Medical Genetics , Nanjing Medical University , Nanjing , Jiangsu , P.R. China

2. Pancreas Centre, Department of General Surgery , The First Affiliated Hospital with Nanjing Medical University , Nanjing , P.R. China

Abstract

Abstract Objectives To explore the role of dual-specific phosphatase 1 (DUSP1) in the proliferation, migration and invasion of pancreatic cancer (PC). Methods TCGA and GTEx databases were used to investigate the relationship between DUSP1 expression and prognosis of PC patients. Expression efficiency of DUSP1 was validated by qPCR and western blotting. The proliferation of SW1990 and PANC-1 cells with DUSP1 overexpression or knockout was detected by EdU assays. The migratory and invasive abilities of cells were detected by wound healing and transwell assays. Results DUSP1 was highly expressed in PC and associated with poor prognosis of patients. Overexpression of DUSP1 promoted the proliferation, migration and invasion of PC cells by regulating nephronectin (NPNT), whereas knockout of DUSP1 exhibited the opposite effects. NPNT expression was positively correlated with DUSP1, and the overall survival of PC patients with high levels of NPNT was shorter. Conclusions DUSP1 promoted the proliferation, migration and invasion of PC cells by upregulating NPNT, suggesting DUSP1 may be a potential target for PC treatment.

Funder

National Natural Science Foundation of China

The Major Projects of Science and Technology Development Fund of Nanjing Medical University

Publisher

Walter de Gruyter GmbH

Subject

Oncology

Link

https://www.degruyter.com/document/doi/10.1515/oncologie-2023-0215/pdf

Reference27 articles.

1. Siegel, RL, Miller, KD, Wagle, NS, Jemal, A. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17–48. https://doi.org/10.3322/caac.21763.

2. Chen, X, Zeh, HJ, Kang, R, Kroemer, G, Tang, D. Cell death in pancreatic cancer: from pathogenesis to therapy. Nat Rev Gastroenterol Hepatol 2021;18:804–23. https://doi.org/10.1038/s41575-021-00486-6.

3. Quinonero, F, Mesas, C, Doello, K, Cabeza, L, Perazzoli, G, Jimenez-Luna, C, et al.. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. Cancer Biol Med 2019;16:688–99. https://doi.org/10.20892/j.issn.2095-3941.2019.0252.

4. Nunes-Xavier, C, Roma-Mateo, C, Rios, P, Tarrega, C, Cejudo-Marin, R, Tabernero, L, et al.. Dual-specificity MAP kinase phosphatases as targets of cancer treatment. Anticancer Agents Med Chem 2011;11:109–32. https://doi.org/10.2174/187152011794941190.

5. Bermudez, O, Pages, G, Gimond, C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol 2010;299:C189–202. https://doi.org/10.1152/ajpcell.00347.2009.